ledipasvir/sofosbuvir

ApprovedSmall molecule

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

ledipasvir/sofosbuvir is one of 143 small molecule programs targeting Thrombocytopenia. It is currently in Approved.

Indications

Total Trials

Active Trials

142

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombocytopeniaActive, not recruiting

LymphomaActive, not recruiting

Chronic HepatitisActive, not recruiting

Esophageal VaricesActive, not recruiting

Hepatitis CActive, not recruiting

ThrombocytopeniaPreclinical

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Chronic HepatitisApproved

Active, not recruiting

Esophageal VaricesPreclinical

Active, not recruiting

Hepatitis CPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

ledipasvir/sofosbuvir

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Approved

1 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Tafasitamab

Incyte

Preclinical

7 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—9

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hepatitis C3 trials

Study of Hepatitis C Treatment During Pregnancy

Completed·CCatherine Chappell·Phase 1·NCT02683005·9 enrolled

Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 1·NCT02128217·44 enrolled

Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection

Completed·UUniversity Health Network, Toronto·Phase 3·NCT02597166·14 enrolled

Treatment2 trials

Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients

Completed·HHumanity and Health Research Centre·Phase 3·NCT02576314·48 enrolled

DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)

Completed·HHumanity and Health Research Centre·Phase 2/3·NCT02555943·23 enrolled

Chronic Hepatitis2 trials

Chronic Hepatitis C Treatment in Egyptian Children With Gaucher Disease.

Unknown status·MMansoura University Children Hospital·Phase 4·NCT03721627·10 enrolled

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Terminated· Gilead logo

Gilead··NCT02510300·461 enrolled

Thrombocytopenia1 trial

The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia

Unknown status·—·N/A·NCT03169348·50 enrolled

Esophageal Varices1 trial

Impact of Antiviral Therapy on Gastroesophageal Varices.

Completed·PParc de Salut Mar··NCT02758509·237 enrolled

2 more indications

Lymphoma1 trial

Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection

Completed·FFondazione Italiana Linfomi - ETS·Phase 2·NCT02836925·40 enrolled

Unspecified1 trial

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

Terminated·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT02605304·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for ledipasvir/sofosbuvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ledipasvir/sofosbuvir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ledipasvir/sofosbuvir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

ledipasvir/sofosbuvir

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hepatitis C3 trials

Treatment2 trials

Chronic Hepatitis2 trials

Thrombocytopenia1 trial

Esophageal Varices1 trial

Lymphoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News